UPC Analytics
DEEN
Übersicht · Eingereicht: —

ACT_3186/2025

INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES

Einstweilige MaßnahmenEinstweilige MaßnahmenLisbon LDApplication for provisional measures—
ÜbersichtEntscheidungenBegründungZitateDokumenteZeitverlauf
Parteien

Kläger

  • Boehringer Ingelheim International GmbH
Vertreter: Joana Catarina Piriquito Santos; Sara Nazaré; Beatriz Lima

Beklagte

  • ZENTIVA PORTUGAL, LDA
Vertreter: Patrícia Paias
Richter
  • Rute LopesPresiding judge, judge-rapporteur
  • Camille LignièresLegally qualified judge
  • Petri RinkinenLegally qualified judge
Patente
  • EP 1 830 843
CPC-Codes: C07D403/12, A61K31/4178, A61K31/4045, A61K31/496, A61K31/495, A61K47/38, A61K9/08, C07D209/34, A61K9/1623, A61K47/10, A61K31/404, A61K9/0031…

Sektor: Organic Chemistry

Ausgang
PI abgelehnt
Eingereicht: —
Erste Entscheidung: 8. Mai 2025
Sprache: —

Lisbon Local Division denied Boehringer Ingelheim International GmbH's application for a preliminary injunction against Zentiva Portugal, LDA concerning EP 1 830 843 (nintedanib for idiopathic pulmonary fibrosis). The court found no imminent infringement: Zentiva's receipt of marketing authorisations and filing of a parallel exclusivity period (PEP) request did not demonstrate that market entry was imminent before patent expiry. The PEP request was filed in the usual course of business and the Defendant was aware of the risk of PEP expiry. Value of case set at EUR 1,000,000.